{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:27:56Z","timestamp":1792520876824,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1335, 360372040"],"award-info":[{"award-number":["SFB1335, 360372040"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1335, 360372040"],"award-info":[{"award-number":["SFB1335, 360372040"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA1236\/10-1"],"award-info":[{"award-number":["MA1236\/10-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BR4733\/1-3"],"award-info":[{"award-number":["BR4733\/1-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BR4733\/3-1"],"award-info":[{"award-number":["BR4733\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Response to immune checkpoint blockade (ICB) in ovarian cancer remains disappointing. Several studies have identified the chemokine CXCL9 as a robust prognosticator of improved survival in ovarian cancer and a characteristic of the immunoreactive subtype, which predicts ICB response. However, the function of CXCL9 in ovarian cancer has been poorly studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Impact of Cxcl9 overexpression in the murine ID8-\n                      <jats:italic>Trp53<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>\u2212\/\u2212<\/jats:italic>\n                      <\/jats:sup>\n                      and ID8-\n                      <jats:italic>Trp53<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>\u2212\/\u2013<\/jats:italic>\n                      <\/jats:sup>\n                      <jats:italic>Brca2<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>\u2212\/\u2212<\/jats:italic>\n                      <\/jats:sup>\n                      ovarian cancer models on survival, cellular immune composition, PD-L1 expression and anti-PD-L1 therapy. CXCL9 expression analysis in ovarian cancer subtypes and correlation to reported ICB response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CXCL9 overexpression resulted in T-cell accumulation, delayed ascites formation and improved survival, which was dependent on adaptive immune function. In the ICB-resistant mouse model, the chemokine was sufficient to enable a successful anti-PD-L1 therapy. In contrast, these effects were abrogated in\n                      <jats:italic>Brca2<\/jats:italic>\n                      -deficient tumours, most likely due to an already high intrinsic chemokine expression. Finally, in ovarian cancer patients, the clear-cell subtype, known to respond best to ICB, displayed a significantly higher proportion of CXCL9\n                      <jats:sup>high<\/jats:sup>\n                      tumours than the other subtypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CXCL9 is a driver of successful ICB in preclinical ovarian cancer. Besides being a feasible predictive biomarker, CXCL9-inducing agents thus represent attractive combination partners to improve ICB in this cancer entity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-022-01763-0","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:04:54Z","timestamp":1647875094000},"page":"1470-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer"],"prefix":"10.1038","volume":"126","author":[{"given":"Stefanie","family":"Seitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias F.","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-5433","authenticated-orcid":false,"given":"Katja","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinde","family":"Br\u00e4uer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Scheutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Multhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilko","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Kiechle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Magdolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-6738","authenticated-orcid":false,"given":"Holger","family":"Bronger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"1763_CR1","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonzalez-Martin A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148\u201359.","journal-title":"Ann Oncol"},{"key":"1763_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14728214.2020.1836155","volume":"25","author":"D Lorusso","year":"2020","unstructured":"Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, et al. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. Expert Opin Emerg Drugs. 2020;25:445\u201353.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1763_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1055\/a-1475-4335","volume":"81","author":"H Bronger","year":"2021","unstructured":"Bronger H. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects. Geburtshilfe Frauenheilkd. 2021;81:1128\u201344.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1763_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl J Med. 2003;348:203\u201313.","journal-title":"N. Engl J Med"},{"key":"1763_CR5","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104:3360\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1763_CR6","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1763_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859\u201374.","journal-title":"Immunity"},{"key":"1763_CR8","doi-asserted-by":"publisher","first-page":"23684","DOI":"10.1073\/pnas.2002806117","volume":"117","author":"IX Chen","year":"2020","unstructured":"Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, et al. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proc Natl Acad Sci USA. 2020;117:23684\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1763_CR9","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity. 2019;50:1498\u2013512.","journal-title":"Immunity"},{"key":"1763_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26:487\u2013504.","journal-title":"Clin Cancer Res"},{"key":"1763_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184:596\u2013614.","journal-title":"Cell"},{"key":"1763_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/bjc.2016.172","volume":"115","author":"H Bronger","year":"2016","unstructured":"Bronger H, Singer J, Windmuller C, Reuning U, Zech D, Delbridge C, et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer. 2016;115:553\u201363.","journal-title":"Br J Cancer"},{"key":"1763_CR13","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35:885\u2013900.","journal-title":"Cancer Cell"},{"key":"1763_CR14","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res"},{"key":"1763_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Research Network.","year":"2011","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"1763_CR16","doi-asserted-by":"publisher","first-page":"680413","DOI":"10.3389\/fgene.2021.680413","volume":"12","author":"X Huo","year":"2021","unstructured":"Huo X, Sun H, Liu S, Liang B, Bai H, Wang S, et al. Identification of a prognostic signature for ovarian cancer based on the microenvironment genes. Front Genet. 2021;12:680413.","journal-title":"Front Genet"},{"key":"1763_CR17","doi-asserted-by":"publisher","unstructured":"Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020; https:\/\/doi.org\/10.1016\/j.annonc.2020.05.019.","DOI":"10.1016\/j.annonc.2020.05.019"},{"key":"1763_CR18","doi-asserted-by":"crossref","unstructured":"Zheng M, Mullikin H, Hester A, Czogalla B, Heidegger H, Vilsmaier T, et al. Development and validation of a novel 11-gene prognostic model for serous ovarian carcinomas based on lipid metabolism expression profile. Int J Mol Sci. 2020;21:9169.","DOI":"10.3390\/ijms21239169"},{"key":"1763_CR19","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-17-0246","volume":"23","author":"C Wang","year":"2017","unstructured":"Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney GL, et al. Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes. Clin Cancer Res. 2017;23:4077\u201385.","journal-title":"Clin Cancer Res"},{"key":"1763_CR20","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26:4268\u201379.","journal-title":"Clin Cancer Res"},{"key":"1763_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170:927\u201338.","journal-title":"Cell"},{"key":"1763_CR22","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","volume":"76","author":"J Walton","year":"2016","unstructured":"Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, et al. CRISPR\/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res. 2016;76:6118\u201329.","journal-title":"Cancer Res"},{"key":"1763_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.","journal-title":"Nat Commun"},{"key":"1763_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ijc.2910520115","volume":"52","author":"V M\u00f6bus","year":"1992","unstructured":"M\u00f6bus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W, et al. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer. 1992;52:76\u201384.","journal-title":"Int J Cancer"},{"key":"1763_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep."},{"key":"1763_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.29","volume":"6","author":"C Windm\u00fcller","year":"2017","unstructured":"Windm\u00fcller C, Zech D, Avril S, Boxberg M, Dawidek T, Schmalfeldt B, et al. CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients. Oncogenesis. 2017;6:e331.","journal-title":"Oncogenesis"},{"key":"1763_CR27","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol. 2021;39:1842\u201355.","journal-title":"J Clin Oncol"},{"key":"1763_CR28","doi-asserted-by":"publisher","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019; https:\/\/doi.org\/10.1001\/jamaoncol.2019.1048.","DOI":"10.1001\/jamaoncol.2019.1048"},{"key":"1763_CR29","doi-asserted-by":"crossref","unstructured":"Drew Y, Kaufman B, Banerjee S, Lortholary A, Hong SH, Park YH, et al. Phase II study of olaparib plus durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Annal Oncol. 2019;30:v485\u20136.","DOI":"10.1093\/annonc\/mdz253.016"},{"key":"1763_CR30","doi-asserted-by":"publisher","first-page":"S615","DOI":"10.1016\/j.annonc.2020.08.953","volume":"31","author":"Y Drew","year":"2020","unstructured":"Drew Y, Penson RT, O\u2019Malley DM, Kim JW, Zimmermann S, Roxburgh P, et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2020;31:S615\u20136.","journal-title":"Ann Oncol"},{"key":"1763_CR31","doi-asserted-by":"crossref","first-page":"175883592094411","DOI":"10.1177\/1758835920944116","volume":"12","author":"EK Lee","year":"2020","unstructured":"Lee EK, Konstantinopoulos PA. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. Therapeutic Adv Med Oncol. 2020;12:1758835920944116.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"1763_CR32","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587\u201398.","journal-title":"Oncotarget"},{"key":"1763_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12865-020-00396-3","volume":"22","author":"W Xiu","year":"2021","unstructured":"Xiu W, Luo J. CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling. BMC Immunol. 2021;22:3.","journal-title":"BMC Immunol"},{"key":"1763_CR34","doi-asserted-by":"publisher","unstructured":"Bronger H. Immunology and immune checkpoint inhibition in ovarian cancer\u2014current aspects. Geburtshilfe und Frauenheilkunde. 2021; https:\/\/doi.org\/10.1055\/a-1475-4335.","DOI":"10.1055\/a-1475-4335"},{"key":"1763_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4384-8","volume":"18","author":"C Zhang","year":"2018","unstructured":"Zhang C, Li Z, Xu L, Che X, Wen T, Fan Y, et al. CXCL9\/10\/11, a regulator of PD-L1 expression in gastric cancer. BMC Cancer. 2018;18:462.","journal-title":"BMC Cancer"},{"key":"1763_CR36","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","volume":"24","author":"BW Higgs","year":"2018","unstructured":"Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, et al. Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin Cancer Res. 2018;24:3857\u201366.","journal-title":"Clin Cancer Res"},{"key":"1763_CR37","doi-asserted-by":"publisher","first-page":"107873","DOI":"10.1016\/j.celrep.2020.107873","volume":"32","author":"Y Qu","year":"2020","unstructured":"Qu Y, Wen J, Thomas G, Yang W, Prior W, He W, et al. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment. Cell Rep. 2020;32:107873.","journal-title":"Cell Rep."},{"key":"1763_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93113-y","volume":"11","author":"T Iwai","year":"2021","unstructured":"Iwai T, Sugimoto M, Patil NS, Bower D, Suzuki M, Kato C, et al. Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab. Sci Rep. 2021;11:13912.","journal-title":"Sci Rep."},{"key":"1763_CR39","doi-asserted-by":"publisher","first-page":"100600","DOI":"10.1016\/j.gore.2020.100600","volume":"33","author":"J Terzic","year":"2020","unstructured":"Terzic J, Seipel A, Dubuisson J, Tille JC, Tsantoulis P, Addeo A, et al. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. Gynecologic Oncol Rep. 2020;33:100600.","journal-title":"Gynecologic Oncol Rep."},{"key":"1763_CR40","doi-asserted-by":"publisher","first-page":"10619","DOI":"10.7150\/thno.44871","volume":"10","author":"QF Zhang","year":"2020","unstructured":"Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, et al. CDK4\/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics. 2020;10:10619\u201333.","journal-title":"Theranostics"},{"key":"1763_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527:249\u201353.","journal-title":"Nature"},{"key":"1763_CR42","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25:2972\u201380. e2975","journal-title":"Cell Rep."},{"key":"1763_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311\u20139.","journal-title":"Cancer Res"},{"key":"1763_CR44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9:722\u201337.","journal-title":"Cancer Discov"},{"key":"1763_CR45","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.18632\/oncotarget.24770","volume":"9","author":"V Wieser","year":"2018","unstructured":"Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, et al. BRCA1\/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. Oncotarget. 2018;9:17501\u201311.","journal-title":"Oncotarget"},{"key":"1763_CR46","doi-asserted-by":"crossref","unstructured":"Liu YL, Selenica P, Zhou Q, Iasonos A, Callahan M, Feit NZ, et al. BRCA mutations, homologous DNA repair deficiency, tumor mutational burden, and response to immune checkpoint inhibition in recurrent ovarian cancer. JCO Precis Oncol. 2020;4:665\u201379.","DOI":"10.1200\/PO.20.00069"},{"key":"1763_CR47","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","volume":"38","author":"RT Penson","year":"2020","unstructured":"Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164\u201374.","journal-title":"J Clin Oncol"},{"key":"1763_CR48","doi-asserted-by":"crossref","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015;33:4015\u201322.","DOI":"10.1200\/JCO.2015.62.3397"},{"key":"1763_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ygyno.2019.05.021","volume":"154","author":"JF Liu","year":"2019","unstructured":"Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced\/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019;154:314\u201322.","journal-title":"Gynecol Oncol."},{"key":"1763_CR50","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30:1080\u20137.","journal-title":"Ann Oncol"},{"key":"1763_CR51","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1200\/JCO.2020.38.15_suppl.6005","volume":"38","author":"UA Matulonis","year":"2020","unstructured":"Matulonis UA, Shapira R, Santin A, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Final results from the Phase 2 KEYNOTE\u2011100 study. ASCO 2020. J Clin Oncol. 2020;38(15_Suppl):6005.","journal-title":"J Clin Oncol"},{"key":"1763_CR52","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5:393\u2013401.","journal-title":"JAMA Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01763-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01763-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01763-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T19:04:28Z","timestamp":1652209468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01763-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,6,1]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01763-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"30 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KS receives research funding from Roche and is a member of the advisory board of TRIMT GmbH. She also has filed a patent on a radiopharmaceutical compound. WW was as a member of advisory boards and speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK and Molecular Health, and he reports research funding from Roche, MSD, BMS and AstraZeneca, all outside of the submitted work. MK reports renumerations von Springer Press, Biermann Press, Celgene, AstraZeneca, Myriad Genetics, TEVA, Eli Lilly, GSK, consulting for Myriad Genetics, Bavarian KVB, DKMS Life, BLAEK, TEVA, Exeltis, equity ownership in Therawis Diagnostic GmbH, AIM GmbH, funding from Sphingotec, Deutsche Krebshilfe, DFG, Senator Roesner Foundation, Dr. Pommer-Jung Foundation, Waltraut Bergmann Foundation, Bavarian State Ministry of Economy, BMBF. VM reports two other non-project-related grants from the Bavarian Ministry of Economy, Infrastructure, Transportation and Technology and from Therawis Diagnostics, respectively. HB reports grants from Deutsche Forschungsgemeinschaft (DFG), German Research Foundation during the conduct of the study, as well as personal fees from Roche, AstraZeneca, GlaxoSmithKline, Clovis, Teva, PharmaMar, and Pfizer outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Use of human samples was approved by the Institutional Review Board of the Technical University of Munich (Munich, Germany; approval 5747\/13). Animal experiments were approved by the Government of Upper Bavaria (Regierung von Oberbayern) and were in accordance with the institutional guidelines of the Technical University of Munich. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}